Haleon Shareholders Back All Resolutions at 2026 AGM, Endorsing Board and Capital Flexibility

An announcement from Haleon PLC ( (GB:HLN) ) is now available.

Haleon plc reported the voting results of its 2026 annual general meeting, where shareholders approved all resolutions on the agenda by substantial majorities. Ordinary resolutions included receiving the annual report and accounts, approving the directors’ remuneration report and policy, confirming a final dividend, re-electing all standing directors, electing Matthew Shattock to the board, reappointing KPMG as auditor and authorising the audit committee to set auditor remuneration.

Shareholders also backed authorities for political donations, the allotment of ordinary shares and several special resolutions, including the disapplication of pre-emption rights, the ability to call general meetings on 14 days’ notice and authority for the company to repurchase its own shares. Around 85% of the issued share capital voted, signalling strong investor engagement and broadly endorsing Haleon’s governance, capital allocation flexibility and board composition, which together support its strategic and financial manoeuvrability in the consumer health sector.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc is a consumer health company focused on improving everyday health through a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other categories. Its brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, which are used by over one billion consumers and recommended by health professionals worldwide.

Average Trading Volume: 21,724,389

Technical Sentiment Signal: Sell

Current Market Cap: £31.14B

See more data about HLN stock on TipRanks’ Stock Analysis page.